Neurocrine Biosciences, Inc. (NBIX) Insider Sells $6,764,341.76 in Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) insider Dimitri E. Grigoriadis sold 86,368 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $78.32, for a total transaction of $6,764,341.76. Following the transaction, the insider now owns 154,717 shares of the company’s stock, valued at $12,117,435.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Neurocrine Biosciences, Inc. (NASDAQ NBIX) traded up $1.52 during midday trading on Tuesday, hitting $83.69. 778,785 shares of the company’s stock were exchanged, compared to its average volume of 1,026,033. The company has a market capitalization of $7,330.00, a PE ratio of -37.70, a PEG ratio of 13.14 and a beta of 0.26. Neurocrine Biosciences, Inc. has a 12-month low of $39.21 and a 12-month high of $91.82. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05.

Institutional investors have recently modified their holdings of the stock. First Trust Advisors LP grew its stake in shares of Neurocrine Biosciences by 29.0% in the third quarter. First Trust Advisors LP now owns 782,685 shares of the company’s stock worth $47,963,000 after purchasing an additional 176,136 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Neurocrine Biosciences by 2.6% in the third quarter. Janus Henderson Group PLC now owns 5,507,763 shares of the company’s stock worth $337,516,000 after purchasing an additional 140,639 shares during the last quarter. Davidson Kempner Capital Management LP bought a new stake in shares of Neurocrine Biosciences in the second quarter worth $3,639,000. State Street Corp grew its stake in shares of Neurocrine Biosciences by 5.1% in the second quarter. State Street Corp now owns 2,710,196 shares of the company’s stock worth $124,666,000 after purchasing an additional 131,141 shares during the last quarter. Finally, Moody Aldrich Partners LLC grew its stake in shares of Neurocrine Biosciences by 13.2% in the third quarter. Moody Aldrich Partners LLC now owns 22,256 shares of the company’s stock worth $1,364,000 after purchasing an additional 2,591 shares during the last quarter.

Several brokerages have commented on NBIX. BidaskClub upgraded shares of Neurocrine Biosciences from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, January 31st. Oppenheimer set a $95.00 price objective on shares of Neurocrine Biosciences and gave the company a “buy” rating in a research report on Monday, January 15th. Needham & Company LLC boosted their price objective on shares of Neurocrine Biosciences to $95.00 and gave the company a “buy” rating in a research report on Tuesday, January 16th. Jefferies Group boosted their price objective on shares of Neurocrine Biosciences to $105.00 and gave the company a “buy” rating in a research report on Friday, January 5th. Finally, Robert W. Baird reaffirmed a “buy” rating and set a $84.00 target price on shares of Neurocrine Biosciences in a research note on Friday, November 3rd. One equities research analyst has rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $84.13.

ILLEGAL ACTIVITY WARNING: “Neurocrine Biosciences, Inc. (NBIX) Insider Sells $6,764,341.76 in Stock” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/02/13/neurocrine-biosciences-inc-nbix-insider-sells-6764341-76-in-stock.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Insider Buying and Selling by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply